CorestemChemon (KOSDAQ: 166480) is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic ...
The assays were shipped to ALS Global in Moncton New Brunswick for preparation with final analysis of pulps conducted in Vancouver, British Columbia. The primary analytical method for the Wedge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback